ArticleThe Lancet regional health. Europe2023
Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study.
Article in The Lancet regional health. Europe, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Pooled it
- Incidence of thrombosis in patients with hepatocellular carcinoma: systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2025Pooled it
- Burden and distribution of venous thromboembolism across cancer types and stages: a meta-analysis of observational studies.Frontiers in oncology · 2025Pooled it
- Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study.American journal of hematology · 2026Article
- Natural History of Treated and Untreated Bland Portal Vein Thrombosis in Patients with Hepatocellular Carcinoma.Cancers · 2026Article
- Development and validation of venous thromboembolism-bidirectional encoder representations from transformers (VTE-BERT) natural language processing model.Journal of thrombosis and haemostasis : JTH · 2026Article
- Prediction of cancer-associated thrombosis by machine learning: results from the Vienna Cancer and Thrombosis Study.ESMO open · 2026Article
- When Cancer Clots: An Extensive Radiologic Analysis of Cancer-Associated Thromboembolism.Cancers · 2026Review
- Association of a Cancer Diagnosis and Mortality After Ischemic and Hemorrhagic Stroke and Myocardial Infarction.Neurology · 2026Article
- Predictive Role of Pre-Radiotherapy D-Dimer and Inflammatory Markers in Monitoring Outcomes After Treatment in Hormone-Positive Breast Cancer: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Understanding Cardio-Oncology: A Survey-Based Study Conducted by the Heart Failure Association of the Polish Cardiac Society and the Polish Society of Clinical Oncology.Journal of clinical medicine · 2026Article
- Development and validation of a preoperative nomogram for predicting venous thromboembolism risk after gynecologic oncology surgery.Discover oncology · 2026Article
- Risk prediction model for thrombosis in leukemia patients: a systematic review.Frontiers in oncology · 2026Review
- Venous Thromboembolism Management and Anticoagulation Opportunities in Cancer Patients.European cardiology · 2026Review
- From signal to significance: characterizing anthracycline-related hypercoagulable adverse events via pharmacovigilance, animal models, and clinical observation.Frontiers in pharmacology · 2026Article
- Risk stratification of in-hospital venous thromboembolism for urological cancers: a multicenter retrospective study.Therapeutic advances in medical oncology · 2026Article
- Development and validation of an interpretable machine learning model for venous thromboembolism risk prediction in patients with lung cancer: a real-world study.Frontiers in medicine · 2026Article
- Atopic dermatitis, venous thromboembolism and cancer: a cohort analysis.Journal of thrombosis and thrombolysis · 2025Article
- Management of cancer-associated venous thromboembolism: Perspectives on optimizing current therapeutics with a focus on factor XI inhibition.Journal of thrombosis and thrombolysis · 2025Review
- Macrovascular tumor infiltration and circulating tumor cell cluster dynamics in patients with cancer approaching the end of life.Nature medicine · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite recent improvements in the treatment of cancer, little is known about the long-term survival in patients with cancer and venous thromboembolism. We aimed to examine the five-year mortality of venous thromboembolism in cancer patients in a large population-based cohort study. Methods: Using Danish healthcare registries from 1995 to 2020, we obtained data on cancer patients with venous thromboembolism and comparison cohorts of cancer patients without venous thromboembolism, matched in terms of cancer type, age, sex, and year of cancer diagnosis, and adjusted for level of comorbidity and frailty using the Charlson Comorbidity Index Score and Hospital Frailty Risk Score, marital status, use of selected medications, and recent surgery (<90 days). Findings: During the study period, 886,536 patients were diagnosed with cancer. Of 1882 cancer patients diagnosed at the time of their venous thromboembolism, 44.4% (835/1882) had distant metastases. In this cohort, the one- and five-year mortality cumulative incidences were 68% (1284/1882) and 84% (1578/1882), respectively, in contrast to 38% (2135/5549) and 67% (3653/5549) in the comparison cohort. The mortality rate ratio was 4.34 (95% confidence interval [CI], 3.95-4.78) for the first year of follow-up and 3.44 (95% CI 3.17-3.73) for the five-year follow-up period. Of the 23,366 patients diagnosed with venous thromboembolism after cancer diagnosis, 18% (4183/23,366) had distant metastases at the time of cancer diagnosis. The cumulative incidence of death at one year was 45% (10,465/23,366; mortality rate ratio 3.48, 95% CI 3.37-3.60) and at five years 69% (15,669/23,366; mortality rate ratio 2.57, 95% CI 2.50-2.63). Interpretation: Despite improved cancer treatment, venous thromboembolism in cancer patients is strongly associated with a poor prognosis. Funding: The study was supported by grants from the Independent Research Fund Denmark (record no. 3101-00102B) and the Karen Elise Jensen Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.